Advertisement

Biomarkers in Neuropsychiatry: A Prospect for the Twenty-First Century?

  • Judith PrattEmail author
  • Jeremy Hall
Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 40)

Abstract

The search for biomarkers to aid in the diagnosis and prognosis of psychiatric conditions and predict response to treatment is a focus of twenty-first century medicine. The current lack of biomarkers in routine use is attributable in part to the existing way mental health conditions are diagnosed, being based upon descriptions of symptoms rather than causal biological evidence. New ways of conceptualizing mental health disorders together with the enormous advances in genetic, epidemiological, and neuroscience research are informing the brain circuits and physiological mechanisms underpinning behavioural constructs that cut across current diagnostic DSM-5 categories. Combining these advances with ‘Big Data’, analytical approaches offer new opportunities for biomarker development. Here we provide an introductory perspective to this volume, highlighting methodological strategies for biomarker identification; ranging from stem cells, immune mechanisms, genomics, imaging, network science to cognition. Thereafter we emphasize key points made by contributors on affective disorders, psychosis, schizophrenia, and autism spectrum disorder. An underlying theme is how preclinical and clinical research are informing biomarker development and the importance of forward and reverse translation approaches. In considering the exploitation of biomarkers we note that there is a timely opportunity to improve clinical trial design informed by patient ‘biological’ and ‘psychological’ phenotype. This has the potential to reinvigorate drug development and clinical trials in psychiatry. In conclusion, we are poised to move from the descriptive and discovery phase to one where biomarker panels can be evaluated in real-life cohorts. This will necessitate resources for large-scale collaborative efforts worldwide. Ultimately this will lead to new interventions and personalized medicines and transform our ability to prevent illness onset and treat complex psychiatric disorders more effectively.

Keywords

Affective disorders Autism spectrum disorder Diagnostic biomarker Early intervention Forward and reverse translation Genetics Genomics Immune Inflammation Patient stratification Personalized medicines Predictive biomarker Prognosis biomarker Psychosis Schizophrenia Stem cells 

References

  1. Andrews DS, Marquand A, Ecker C, McAlonan G (2018) Using pattern classification to identify brain imaging markers in autism spectrum disorder.  https://doi.org/10.1007/7854_2018_47 Google Scholar
  2. Battaglia M, Khan WU (2018) Reappraising preclinical models of separation anxiety disorder, panic disorder, and CO2 sensitivity: implications for methodology and translation into new treatments.  https://doi.org/10.1007/7854_2018_42 Google Scholar
  3. Herron JW, Nerurkar L, Cavanagh J (2018) Neuroimmune biomarkers in mental illness.  https://doi.org/10.1007/7854_2018_45 Google Scholar
  4. Hunter SA, Lawrie SM (2018) Imaging and genetic biomarkers predicting transition to psychosis.  https://doi.org/10.1007/7854_2018_46 Google Scholar
  5. Johnstone M, Hillary RF, St Clair D (2018) Stem cells to inform the neurobiology of mental illness.  https://doi.org/10.1007/7854_2018_57 Google Scholar
  6. Kalia M, Costa E, Silva J (2015) Biomarkers of psychiatric diseases: current status and future prospects. Metab Clin Exp.  https://doi.org/10.1016/j.metabol.2014.10.026 CrossRefGoogle Scholar
  7. Lydon-Staley DM, Bassett DS (2018) Network neuroscience: a framework for developing biomarkers in psychiatry.  https://doi.org/10.1007/7854_2018_41 Google Scholar
  8. MacQueen DA, Young JW, Cope ZA (2018) Cognitive phenotypes for biomarker identification in mental illness: forward and reverse translation.  https://doi.org/10.1007/7854_2018_50 Google Scholar
  9. Maron E, Lan C-C, Nutt D (2018) Imaging and genetic approaches to inform biomarkers for anxiety disorders, obsessive–compulsive disorders, and PSTD.  https://doi.org/10.1007/7854_2018_49 Google Scholar
  10. Notter T (2018) Immunological processes in schizophrenia pathology: potential biomarkers?  https://doi.org/10.1007/7854_2018_43 Google Scholar
  11. Prata D, Mechelli A, Kapur S (2014) Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. Neurosci Biobehav Rev 45:134–141.  https://doi.org/10.1016/j.neubiorev.2014.05.010 CrossRefPubMedGoogle Scholar
  12. Pratt JA, Morris BJ, Dawson N (2018) Deconstructing schizophrenia: advances in preclinical models for biomarker identification.  https://doi.org/10.1007/7854_2018_48 Google Scholar
  13. Reddaway JT, Doherty JL, Lancaster T, Linden DE, Walters J, Hall J (2018) Genomic and imaging biomarkers in schizophrenia.  https://doi.org/10.1007/7854_2018_52 Google Scholar
  14. Scarr E et al (2015) Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP think tank. Int J Neuropsychopharmacol 18(10):pyv042.  https://doi.org/10.1093/ijnp/pyv042 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Slaney C, Hinchcliffe JK, Robinson ESJ (2018) Translational shifts in preclinical models of depression: implications for biomarkers for improved treatments.  https://doi.org/10.1007/7854_2018_44 Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Strathclyde Institute of Pharmacy and Biomedical SciencesUniversity of StrathclydeGlasgowUK
  2. 2.Neuroscience and Mental Health Research InstituteCardiff UniversityCardiffUK

Personalised recommendations